RMTI

5.8207.03%
RS

Robert Samuel Radie

Independent Chairman

Mr. Robert Samuel Radie, also known as Bob, is Director of Valsource, Inc. Mr. Radie has been the Chairman of the Board and Chief Executive Officer of Neuraptive Therapeutics, Inc. since July 2020. He serves as Independent Board Member at Orcosa Inc since January 2024. Mr. Radie had been an Independent Outside Director of Paratek Pharmaceuticals, Inc. since October 30, 2014 until September 21, 2023. Mr. Radie has been an Independent Chairman at Rockwell Medical, Inc. since April 2022 and also has been its Independent Director since March 31, 2020. He has been a Director at Life Sciences Pennsylvania since May 2015. Mr. Radie was Senior Vice President of Sales at Vicuron Pharmaceuticals LLC. He served as Director at Veloxis Pharmaceuticals A/S from July 27, 2016 to February 2020. Mr. Radie was the President, Chief Executive Officer from March 2012 to October 22, 2019 at Zyla Life Sciences and was Director from March 2012 to October 22, 2019 and was Principal Financial Officer at Zyla Life Sciences from April 29, 2019 to December 31, 2019. From March 2009 to November 2010. Mr. Radie served as the President and Chief Executive Officer of Transmolecular, Inc., a biotechnology company, after serving as a Consultant to Transmolecular from December 2008 to March 2009. Mr. Radie served as the Chief Business Officer at MORPHOTEK INC. He served as a Director at Affinium Pharmaceuticals, Ltd from July 2012 to March 2014. Mr. Radie served as the Chief Business Officer at Prestwick Pharmaceuticals, Inc. from September 2007 to September 2008 and was its Executive Vice President since August 23, 2007. Mr. Radie was the Chief Executive Officer, President and Director at Sanofi-Topaz Inc. since November 17, 2010 until October 2011. Mr. Radie was Director at Veloxis Pharmaceuticals, Inc. until 2020. Mr. Radie has years of industry experience, working in both public and private pharmaceutical and biotech companies and across a range of therapeutic areas. From November 2010 to October 2011. Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc. Before joining Prestwick. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and Eli Lilly and Company. Mr. Radie has been a Member of the board of directors of ValSource Inc. since October 2020 and served as a Director of Horse Power for Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, from 2006 to 2024. Mr. Radie serves on the Board of Directors of several companies, including Rockwell Medical Technologies Inc. He also serves as a Member of the Board of Directors of Life Sciences Pennsylvania (LSPA), the Pennsylvania industry advocacy group. Mr. Radie completed Bachelors of Science Degree in Chemistry from Boston College. He has served as board chairman of Monument Therapeutics since April 2025. He has also served as a director of Biograil, Inc. since December 2025.

Positions